Kane Biotech Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was CAD 0.541302 million compared to CAD 0.360603 million a year ago. Net loss was CAD 1.52 million compared to CAD 1.03 million a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago. For the nine months, revenue was CAD 1.2 million compared to CAD 1.08 million a year ago. Net loss was CAD 3.34 million compared to CAD 2.9 million a year ago. Basic loss per share from continuing operations was CAD 0.03 compared to CAD 0.03 a year ago.